The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Abstract
Objective: To assess the safety of sitagliptin in patients with type 2 diabetes and moderate [creatinine clearance (CrCl) ≥30 to <50 ml/min] or severe renal insufficiency [CrCl <30 ml/min including patients with end‐stage renal disease (ESRD) on dialysis]. The efficacy of sitagliptin in this patient population was also assessed. Methods: In a 54‐week, randomized, double‐blind, parallel‐group study, patients with baseline glycosylated haemoglobin A 1c (HbA 1c ) values of 6.5–10% were allocated (2:1) to sitagliptin (for 54 weeks) or the sequence of placebo (for 12 weeks) followed by active treatment with glipizide (for 42 weeks). To achieve plasma concentrations similar to those observed in patients with normal renal function treated with 100 mg sitagliptin once daily, patients with moderate renal insufficiency were allocated to receive sitagliptin 50 mg once daily and patients with severe renal insufficiency to receive 25 mg once daily. Glipizide treatment was initiated at 2.5 or 5 mg/day and uptitrated to a maximum of 20 mg/day. Results: Patients (N = 91) with a mean baseline HbA 1c value of 7.7% (range: 6.2–10.3%) were randomized to sitagliptin (n = 65) or placebo (n = 26). After 12 weeks, the mean change [95% confidence interval (CI)] from baseline in HbA 1c was −0.6% (−0.8, −0.4) in the sitagliptin group compared with −0.2% (−0.4, 0.1) in the placebo group [between‐group difference (95% CI) = −0.4% (−0.7, −0.1)]. At 54 weeks, patients continuously treated with sitagliptin had a mean change (95% CI) from baseline in HbA 1c of −0.7% (−0.9, −0.4). The overall incidence of adverse experiences was generally similar between groups. Between‐group differences in incidences of specific clinical adverse experiences were generally small; however, the proportion of patients for whom hypoglycaemia was reported was lower in the sitagliptin group (4.6%) compared with the placebo/glipizide group (23.1%). Consistent with the high mortality risk in this patient population, there were six deaths during this 54‐week study [5 of 65 patients (7.7%) in the sitagliptin group and 1 of 26 patients (3.8%) in the placebo/glipizide group]; no death was considered by the investigator to be drug related. The overall incidences of drug‐related and serious adverse experiences and discontinuations because of adverse experiences were generally similar between groups. Conclusions: In this study, sitagliptin was generally well tolerated and provided effective glycaemic control in patients with type 2 diabetes and moderate to severe renal insufficiency, including patients with ESRD on dialysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Cited by
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Metadata
- Authors
- Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2008-06-28
- Volume
- 10
- Issue
- 7
- Pages
- 545-555
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2075182875
- Cited by
- 238
- References
- 3
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00914.x
- The paper
- Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008). Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00914.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.